Episode 512: ENZA-P Nature Medicine translational data
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Podcast Index
Podcasts
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
Tout
Actualités
Politique
Musique
Sport
Technologie
Comédie
Arts
Business
Éducation
Fiction
Gouvernement
Santé & fitness
Histoire
Enfants & famille
Loisirs
Religion & spiritualité
Science
Société & culture
True crime
TV & cinéma
The Uromigos
The Uromigos
The Front
The Australian
jewish, judaism, spirituality, torah,
Rabbi David Bassous
Et si on parlait français ?
Radio Classique
Group Chat
Chris "Drama" Pfaff, Dee Murthy & Anand Murthy
قراءة في الصحف الفرنسية
مونت كارلو الدولية / MCD
ジェーン・スー 生活は踊る
TBS RADIO
HR Leader Podcast Network
Momentum Media
Philosophy Playdate
Clever Make Funny Productions Ltd
Ö1 Journale
ORF Ö1
Brisbane News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Le podcast BasketSession
Le podcast BasketSession
Darrers podcast - Ràdio Pineda
Ràdio Pineda
Radio Palencia
Cadena SER
Earn Your Happy
Lori Harder | YAP Media
The Chris Harder Show
Chris Harder
FG CHIC
RADIO FG
How to Be Awesome at Your Job
How to be Awesome at Your Job
Radio Rioja
Cadena SER
SER Vitoria
Cadena SER
L'Heure Du Crime
RTL
SER Tarragona
Cadena SER
Radio Motril
Cadena SER
Ràdio Lleida
Cadena SER
A Book with Legs
Smead Capital Management
Radio Calahorra
Cadena SER
Radio Alcoy
Cadena SER
SER Vegas Altas
Cadena SER
Radio Melilla
Cadena SER
SER Poniente
Cadena SER
SER Norte de Extremadura
Cadena SER
Buenas noches, Cráneo: Historias para dormir
Cumbre Kids
English with Frazer - LEARN NATURAL BRITISH ENGLISH
Frazer W
Save Yourself With Dr. Amy Shah
Dr. Amy Shah
Art Market Minute
Artnet News
Radiosveglia
OnePodcast
TheCrispCast
TheCrispGuys
Tout
The Uromigos
The Uromigos
Episode 510: ADCs in Prostate Cancer
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and ...
Episode 509: ASCO 2026 Review
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent stud...
Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
Episode 507: ASCO 2026 - TALAPRO-3
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and inn...
Episode 505 : ASCO 2026 - RAMPART
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts di...
Episode 499: APCCC 2026 - Radioligands in Prostate Cancer
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, c...
Episode 503: ASCO 2026 Preview
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
Episode 502: AUA 2026 and FDA bladder cancer meeting
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of d...
Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer a...
Episode 499: APCCC 2026 - Radioligands
This session from APCCC 2026 features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in current practices, challenges, and future directions in radi...
Episode 498: APCCC 2026 - mCRPC
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-dri...
Episode 497: Reflections on the capivasertib ODAC
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-ri...
Episode 496: APCCC 2026 - mHSPC Landscape
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment d...
Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist
Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
Episode 493: The Role of Chemotherapy in mHSPC
In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights...